643 related articles for article (PubMed ID: 18828174)
61. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
62. Functional inaccessibility of quiescent herpes simplex virus genomes.
Minaker RL; Mossman KL; Smiley JR
Virol J; 2005 Nov; 2():85. PubMed ID: 16300675
[TBL] [Abstract][Full Text] [Related]
63. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis.
Oligino T; Ghivizzani S; Wolfe D; Lechman E; Krisky D; Mi Z; Evans C; Robbins P; Glorioso J
Gene Ther; 1999 Oct; 6(10):1713-20. PubMed ID: 10516720
[TBL] [Abstract][Full Text] [Related]
64. Multiple applications for replication-defective herpes simplex virus vectors.
Burton EA; Wechuck JB; Wendell SK; Goins WF; Fink DJ; Glorioso JC
Stem Cells; 2001; 19(5):358-77. PubMed ID: 11553845
[TBL] [Abstract][Full Text] [Related]
65. ICP27-dependent resistance of herpes simplex virus type 1 to leptomycin B is associated with enhanced nuclear localization of ICP4 and ICP0.
Lengyel J; Strain AK; Perkins KD; Rice SA
Virology; 2006 Sep; 352(2):368-79. PubMed ID: 16780914
[TBL] [Abstract][Full Text] [Related]
66. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
67. Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions.
Song B; Yeh KC; Liu J; Knipe DM
Virology; 2001 Nov; 290(2):320-8. PubMed ID: 11883196
[TBL] [Abstract][Full Text] [Related]
68. Induction of sialyl-Lex expression by herpes simplex virus type 1 is dependent on viral immediate early RNA-activated transcription of host fucosyltransferase genes.
Nyström K; Nordén R; Muylaert I; Elias P; Larson G; Olofsson S
Glycobiology; 2009 Aug; 19(8):847-59. PubMed ID: 19369700
[TBL] [Abstract][Full Text] [Related]
69. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0.
Brehm M; Samaniego LA; Bonneau RH; DeLuca NA; Tevethia SS
Virology; 1999 Apr; 256(2):258-69. PubMed ID: 10191191
[TBL] [Abstract][Full Text] [Related]
70. Cell lines that support replication of a novel herpes simplex virus 1 UL31 deletion mutant can properly target UL34 protein to the nuclear rim in the absence of UL31.
Liang L; Tanaka M; Kawaguchi Y; Baines JD
Virology; 2004 Nov; 329(1):68-76. PubMed ID: 15476875
[TBL] [Abstract][Full Text] [Related]
71. [Herpes simplex virus type 1 ICP27 induces apoptotic cell death by increasing intracellular reactive oxygen species].
Kim JC; Choi SH; Kim JK; Kim Y; Kim HJ; Im JS; Lee SY; Choi JM; Lee HM; Ahn JK
Mol Biol (Mosk); 2008; 42(3):470-7. PubMed ID: 18702305
[TBL] [Abstract][Full Text] [Related]
72. In vivo complementation studies of a glycoprotein H-deleted herpes simplex virus-based vector.
Speck PG; Efstathiou S; Minson AC
J Gen Virol; 1996 Oct; 77 ( Pt 10)():2563-8. PubMed ID: 8887491
[TBL] [Abstract][Full Text] [Related]
73. [Herpes simplex type-1 virus-based vectors for gene therapy].
Ichikawa T; Saeki Y; Tamiya T; Chiocca EA; Ohmoto T
Nihon Rinsho; 2000 Apr; 58(4):822-7. PubMed ID: 10774201
[TBL] [Abstract][Full Text] [Related]
74. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
Mezhir JJ; Advani SJ; Smith KD; Darga TE; Poon AP; Schmidt H; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2005 Oct; 65(20):9479-84. PubMed ID: 16230412
[TBL] [Abstract][Full Text] [Related]
75. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
76. Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential alpha27 gene.
Lium EK; Silverstein S
J Virol; 1997 Nov; 71(11):8602-14. PubMed ID: 9343218
[TBL] [Abstract][Full Text] [Related]
77. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids.
Booth MJ; Mistry A; Li X; Thrasher A; Coffin RS
Gene Ther; 2004 May; 11(10):829-37. PubMed ID: 14985784
[TBL] [Abstract][Full Text] [Related]
78. A haploid HSV-1 genome platform for vector development: testing of the tetracycline-responsive switch shows interference by infected cell protein 0.
Khalique H; López Marco J; Lim F
J Gene Med; 2016 Oct; 18(10):302-311. PubMed ID: 27672733
[TBL] [Abstract][Full Text] [Related]
79. Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis.
Preston CM; Nicholl MJ
J Virol; 1997 Oct; 71(10):7807-13. PubMed ID: 9311867
[TBL] [Abstract][Full Text] [Related]
80. Accumulation of herpes simplex virus type 1 early and leaky-late proteins correlates with apoptosis prevention in infected human HEp-2 cells.
Aubert M; Rice SA; Blaho JA
J Virol; 2001 Jan; 75(2):1013-30. PubMed ID: 11134315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
